Noso Capital
Noso Capital is an independent private capital fund management firm based in Santiago de Compostela, Galicia, Spain. Established in 2019, it is the first privately capitalized SGEIC in Galicia, focusing on investments in technology-based startups and small to medium-sized enterprises (SMEs) that have a positive social impact. The firm combines financial investment with strategic mentorship, offering funding from €200,000 to several million euros, primarily targeting early-stage ventures in the Seed and Series A-B phases. Noso Capital manages specific investment funds that focus on various str
Investing activity
Noso Capital appears in 1 AI deal tracked by the AI Lounge deals desk, and led 1 of them. The rounds are mostly Seed, with a median round size of $4M. The most recent is Healthplus.ai (Seed, $3.8M (EUR 3.3M), Sep 2026).
Noso Capital most often invests alongside Brightlands Venture Partners, ROM InWest, LUMO labs and Pathena, and the companies it backs on AI Lounge are mostly in AI.
Deals
Frequently asked questions about Noso Capital
What AI companies has Noso Capital invested in?
Noso Capital's AI investments include Healthplus.ai. The 1 round on AI Lounge are listed on this page with amounts, dates and co-investors.
Where is Noso Capital based?
Noso Capital is based in Santiago de Compostela, Galicia, Spain.
What stage does Noso Capital invest at?
In the rounds tracked on AI Lounge, Noso Capital has invested at Seed, with a median round of $4M. Noso Capital led 1 of those rounds.
Who does Noso Capital co-invest with?
Noso Capital's most frequent co-investors on AI Lounge are Brightlands Venture Partners (1 deal), ROM InWest (1 deal), LUMO labs (1 deal), Pathena (1 deal) and Elevating Capital (1 deal).
How can founders reach Noso Capital?
Founders on AI Lounge can see Noso Capital's contact details in AI Investor Contacts (paid plans), check for a warm introduction through members who worked with the firm under Warm Paths, and add Noso Capital to their Investor Pipeline to track the conversation.